A clinical trial to compare the effects of giving lignocaine by intravenous or nebulization to reduce the pressor responses during endotracheal intubation and laryngoscopy.
Phase 4
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2022/03/040821
- Lead Sponsor
- Government of Gujarat
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA 1 and 2 patients posted for surgery under general anaesthesia requiring endotracheal intubation.
Exclusion Criteria
Patients with pre existing hypertension, Patients with known allergy to the study drug or contraindication to any of the administered drugs, Patients with anticipated difficult airway, Patients who refused or inability to understand the procedure.
5.Patients who are smokers
6.Patients with History of respiratory distress
7.Patients with gastroesophageal reflux,Neurological ,cardiovascular,respiratory ,hepatic or renal dise
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of efficacy of the NL as compared to IVL in suppressing pressor response to laryngoscopy and intubation <br/ ><br>Timepoint: Starting of nebulized lignocaine/Intravenous lignocaine to 20th minute after endotracheal intubation.
- Secondary Outcome Measures
Name Time Method Evaluation of efficacy of the 2% lignocaine nebulization for 20minutes as compared to 1.5mg/kg intravenous lignocaine bolus in <br/ ><br>suppression of arrhythmias/any other complications if any during laryngoscopy and intubation. <br/ ><br> <br/ ><br>Timepoint: Preoperatively before induction starting of 2% nebulized lignocaine/1.5mg/kg Intravenous lignocaine upto 20 minutes after endotracheal intubation.